List view / Grid view
Scaling up cell therapy is no easy feat. PluriCDMO's Andy Lewin reveals the critical factors for success and how they are helping companies bring life-saving therapies to market.
19 February 2025 | By
Discover the transformative potential of iPSC-based therapies in regenerative medicine, alongside their challenges including scalability, safety and targeted delivery.
Download our latest report to discover how stem cell research is revolutionising treatments for chronic diseases, cancer and regenerative medicine.
Hydrocelin shows promising preclinical results in treating osteoarthritis, offering pain relief and potential joint protection with no observed side effects.
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
Researchers reveal that GPNMB could be an effective therapeutic agent to improve cardiac function and prevent heart failure.
The self-assembly of human liver tissues in low Earth orbit could improve their differentiation and functionality.
Cincinnati Children’s have repaired damaged intestines in a rodent model, moving research efforts closer to clinical trials.
Resolution Therapeutics is pioneering a novel approach to the treatment of chronic liver disease – by engineering the patient’s own macrophages to include regenerative properties. Cliff Brass, Chief Medical Officer at Resolution Therapeutics, explains how the aim is to reduce inflammation, improve liver function, and ultimately eliminate the need for…
Researchers showed that internal stress, induced by active cell behaviours, shapes the Drosophila wing disc pouch during eversion.
A biomaterial that improved hyaline cartilage repair could be used to avoid knee replacements and treat injuries and degenerative diseases.
In this episode, we discuss how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy.
Topological defects in mesenchymal stromal cell self-assembly could suggest their potential for cartilage regeneration.
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
